The impact of financialisation on Global Health: Exploring the influence of investors on the AMR Puzzle Does financialisation explain why we are not producing enough antibiotics?

The paradox of commercial interests and lack of profit precluding both emergence of innovative "new" antibiotics and the production of long extant "old" medicine which is leading to shortages. Examining the issue through specific drug case studies from both ends of the pharmaceutical life cycle pre- and post- commercialisation.